The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...
Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.
Researchers at Australia's WEHI (Walter and Eliza Hall Institute) medical research center applied AI analysis to over 50,000 ...
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...